JOHN P BRANCACCIO
CIK 1276551 · Chairman · last filed 2026-07-23
JOHN P BRANCACCIO is a Chairman who has filed 67 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider was granted $7.4K of OKYO on Jul 23, 2026. Across all open-market trades the lifetime net is +$107.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $145.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$145.6K
10
67
$107.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKYO | Director | 35,201 | $1.64 | $57.7K | $25.0K | 3 | 2026-07-23 |
| Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Chairman | 7 | $0.08 | $1 | $10.7K | 6 | 2024-02-21 |
| CRDF | Director | 12,260 | $0.82 | $10.0K | $42.8K | 6 | 2022-06-09 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | 13,598 | — | — | $16.0K | 7 | 2019-06-24 |
| SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Director | 116,571 | — | — | $23.3K | 5 | 2018-07-06 |
| Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Director | — | — | — | $0 | 2 | 2018-07-03 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Director | — | — | — | $0 | 7 | 2017-01-05 |
| SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Director | 21,883 | — | — | -$14.5K | 11 | 2016-09-21 |
| ACEL | Director | 6,300 | $12.35 | $77.8K | $4.5K | 5 | 2009-01-05 |
| CALLISTO PHARMACEUTICALS INC (KAL) Delisted | Director | — | $1.12 | — | $0 | 1 | 2007-09-28 |
Recent Filings
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-23 | OKYO | Grant (A) | +5,000 | $7.4K | EDGAR |
| 2026-06-10 | OKYO | Grant (A) | — | $0 | EDGAR |
| 2024-02-21 | Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-09-28 | OKYO | Buy (P) | +16,670 | $25.0K | EDGAR |
| 2022-06-09 | CRDF | Other (J) | — | $0 | EDGAR |
| 2022-03-10 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2021-06-14 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2021-05-20 | Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-22 | CRDF | Buy (P) | +3,000 | $32.9K | EDGAR |
| 2020-12-02 | Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Buy (P) | +7,000 | $10.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.